Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2013 Results
Date:5/9/2013

WASHINGTON, May 9, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2013.

Key Highlights:

  • On March 25, 2013, Vanda announced that it held a successful Pre-New Drug Application meeting with the U.S. Food and Drug Administration (FDA).  The FDA confirmed that the efficacy and safety data proposed by Vanda to be submitted in a tasimelteon New Drug Application (NDA) for Non-24-Hour Disorder (Non-24) is adequate to support filing. Vanda is targeting an NDA submission for tasimelteon for Non-24 in mid-2013.
  • Vanda and Bristol-Myers Squibb (BMS) entered into an amendment to the tasimelteon licensing agreement.  Subsequent to this amendment, BMS waived its option to re-acquire rights to develop and commercialize tasimelteon.
  • Full year 2013 decrease in cash, cash equivalents and marketable securities (Cash) is expected to be between $45.0 and $50.0 million, compared to $47.5 million for 2012.  2013 expenses are expected to reflect lower research and development spending as compared to 2012 and an increase in commercial spending that is commensurate to progress with the tasimelteon NDA filing.
  • During the first quarter of 2013, Vanda withdrew its Marketing Authorization Application (MAA) for Fanaptum™ (oral iloperidone tablets) in the European Union.
  • On April 18, 2013, Vanda announced that Paolo Baroldi, M.D., Ph.D. joined its management team as Senior Vice President, Chief Medical Officer.
  • FIRST QUARTER 2013 REPORTED RESULTSTotal revenues for the first quarter of 2013 and 2012 were each $8.1 mi
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
    3. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
    4. Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
    5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
    6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    7. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    8. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    9. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    10. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    11. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... (either DNA or RNA) into cells. This technology helps ... cells and protein metabolism by affecting the nuclear genes. ...
    (Date:7/11/2014)... AZ (PRWEB) July 11, 2014 ... device company specializing in the soft tissue reconstruction ... All-Suture Anchor System for surgeries involving the shoulder ... fixation through a novel, inserter-controlled deployment method. The ... to partial deployment, anchor pull-out, or anchor displacement ...
    (Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
    (Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
    Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
    ... 30 , - Shares Acquired From Biggar ... biotechnology company,focused on eye disease, vascular disease and ... based in Belgium have together acquired an 8%,stake ... Biggar Limited, a,charitable foundation that is ThromboGenics largest ...
    ... July 29 Osteotech, Inc.,(Nasdaq: OSTE ), a ... healing, announced today that the United States Food and ... M(TM),Biocomposite for use in spinal applications. In spinal applications, ... a bone void filler. In,March 2008, Osteotech received FDA ...
    ... 29 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) ... results after the NASDAQ Global Market closes on ... Arena,s President and Chief,Executive Officer, and Robert E. ... will host a conference call at 5:00 p.m.,Eastern ...
    Cached Biology Technology:ThromboGenics Announces Private Investors Acquire 8% Stake in the Company 2ThromboGenics Announces Private Investors Acquire 8% Stake in the Company 3Osteotech's Plexur M(TM) Biocomposite Receives FDA Clearance in Spine 2Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 2Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 3
    (Date:7/11/2014)... to the hippocampus, the marginal division of the ... What is the impact degree of substance P ... memory function? Yan Yu and his team, College ... using immunofluorescence staining, that substance P receptor, neurokinin ... striatal marginal division of normal rats. Unilateral or ...
    (Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
    (Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
    Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
    ... skin and previously considered harmless, may, in fact, be the ... sinuses that strikes more than one in ten Americans each ... of California, San Francisco. The team reports this ... sinusitis may be linked to the loss of normal microbial ...
    ... Society of Interventional Radiology hailed the Sept. 11 ... organization that has oversight of the 24 recognized ... Radiology,s application for a new Dual Primary Certificate ... approval, ABMS and its member boards confirmed the ...
    ... 12, 2012 Glucocorticoids, a group of hormones that ... increase following stress. When their relationship to stress was ... cortisol prepared the body to cope with the physical ... linked to depression and other stress-related disorders, giving rise ...
    Cached Biology News:Sinusitis linked to microbial diversity 2Society of Interventional Radiology hails affirmation of specialty's role in patient care 2Society of Interventional Radiology hails affirmation of specialty's role in patient care 3Society of Interventional Radiology hails affirmation of specialty's role in patient care 4Stress hormones: Good or bad for posttraumatic stress disorder risk? 2
    ...
    ... These primers are designed for sequencing ... the SP6, T7, or T3 RNA polymerase ... They are supplied at a concentration of ... functionally tested in DNA sequencing reactions using ...
    BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
    ... Mouse Antibody to Human Cytokeratin TYPE II ... (Type II) keratins. Including epidermal cell keratin ... 58kD, 65kD and 67kD. Broad keratin reactivity ... and cornea. Immunogen: ...
    Biology Products: